year available), there were 1281 large incidents (≥500 affected individuals) and 164 127 small incidents (<500 affected individuals). In aggregate, the large incidents affected approximately 52 million individuals while the small incidents affected 0.8 million individuals. These statistics suggest that, from a public policy perspective, large incidents have the potential to significantly impact more individuals than small incidents. Thus, larger breach incidents might deserve special attention from the government, industry, and research community. We do agree that all hospitals should take action to mitigate risk of data breaches and that smaller breaches also deserve more transparency because breached patient information does have human consequences, irrespective of the breach size where the information was compromised.

Drs Fabbri et al suggested that our results are affected by the HHS data collection process because only a PHI breach affecting 500 or more individuals requires HHS notification. We disagree. TheHITECHAct requires health plan, health care providers, and business associates (ie, covered entities) to report all PHI breaches to HHS. There is no evidence, to our knowledge, that HHS has not been enforcing the law.

Drs Fabbri et al argued that hospitals that are unable to detect or did not actually detect data breach incidents are excluded from HHS public reporting. This is possible and consistent with the perception that the health care sector has not been an industry leader in information security. However, we believe that the number of these hospitals is likely to be limited because the vigilance of the public may compensate for these hospitals’ lack of detection ability. Patients whose information is compromised usually complain to the hospital or HHS, facilitating the detecting and subsequent reporting of breaches. From 2003 to 2014, the HHS received 108 031 complaints alleging covered entities disclosing patients’ PHI inappropriately.

Ge Bai, PhD, CPA
John (Xuefeng) Jiang, PhD
Renee Flasher, PhD, CPA

Author Affiliations: The Johns Hopkins Carey Business School, Washington, DC (Bai); Eli Broad College of Business, Michigan State University, East Lansing (Jiang); Miller College of Business, Ball State University, Muncie, Indiana (Flasher).

Corresponding Author: Ge Bai, PhD, CPA, The Johns Hopkins Carey Business School, Bernstein-Offit Bldg 353, 1717 Massachusetts Ave NW, Washington, DC 20036 (gbai@jhu.edu).

Conflict of Interest Disclosures: None reported.


Considerations for County-Level Inequalities in Life Expectancy

To the Editor In an Original Investigation published in a recent issue of JAMA Internal Medicine, Dwyer-Lindgren and colleagues showed the existence and growth of alarmingly large inequalities in life expectancy across counties in the United States—up to a disturbing 20-year gap between the highest and lowest life expectancies between counties. I agree with the authors that these findings demand action because inequalities will continue to grow unabatedly in the face of inaction.

Dwyer-Lindgren and colleagues examined as mediators several demographic, socioeconomic, behavioral and metabolic, and health care factors, finding that they accounted for almost 75% of the variation in life expectancy. Importantly, the authors acknowledged the lack of other likely factors driving the inequalities observed. I believe diet quality, alcohol and drug abuse, and housing conditions are some of the critical missing factors in the analysis. In their Figure showing life expectancy by county, Baltimore City stands out in orange (life expectancy ≤75 years) among its green and blue neighboring counties (life expectancy ≥80 years). County-level data from the County Health Rankings project show that the proportion of the Baltimore City population that experiences food insecurity is 24%, twice and thrice that observed in neighboring counties; 24% is also the proportion of households that experience dire housing problems like very high cost burden, severe overcrowding, and lack of kitchen or plumbing facilities—again much higher than in neighboring counties. Finally, with a residential segregation index of 69, Baltimore City remains the most racially segregated county in Maryland. Future research must consider these critical behavioral and structural factors—particularly diet and housing conditions—as mediators of inequalities in life expectancy across counties.

Dwyer-Lindgren and colleagues also found that socioeconomic factors no longer explained the variation in life expectancy when all other factors were considered; thus, the authors suggested that the association between life expectancy and socioeconomic factors is largely mediated by behavioral and metabolic risk factors. I would like to caution against such conclusions, as evidence from large multichart analyses indicates that the observed socioeconomic variation in all-cause and cause-specific mortality—key factors in life expectancy—remains large and significant after behavioral and metabolic factors are accounted for. Doing so risks encouraging public health efforts and resources to focus on the individual, mistakenly ignoring the crucial role of structural forces that drive population and individual behavior, thereby hampering efforts to reduce inequalities in life expectancy.

Carlos de Mestral, MSc
In their Research Letter, Auer et al2 did not present any data regarding the impact of IQOS use on indoor air quality. In contrast, we produced and published data using validated methods that show that the use of IQOS does not negatively impact indoor air quality according to international standards.3

We recognize the need to scrutinize the scientific work performed by the tobacco industry. It would seem equally important to scrutinize the work emanating from academia. We are therefore puzzled that the peer review system did not identify some of the methodological and interpretational findings outlined in our review.4

Philip Morris International transparently communicates its study results,4 including that IQOS yields over 90% lower levels of toxicants than the reference cigarette 3R4F and is not risk free.4,6 The totality of the evidence collected to date, across a broad range of toxicology, systems toxicology, and clinical studies, indicates that IQOS has the potential to present less risk of harm compared with continued smoking for adult smokers who switch to it completely.6

Serge Maeder, PhD
Manuel C. Peitsch, PhD

Author Affiliations: Philip Morris International Testing Laboratories & Analytical Research, Switzerland (Maeder); Philip Morris International, Quai Jeanrenaud 5, 2000 Neuchâtel, Switzerland (Peitsch).

Conflicts of Interest: The authors are fully paid employees of Philip Morris International (PMI), the manufacturer of IQOS. All studies conducted by PMI with IQOS were solely funded by PMI.